Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7900-0.0500 (-2.72%)
At close: 04:00PM EDT
1.8200 +0.03 (+1.68%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8400
Open1.7900
Bid1.7900 x 43500
Ask1.8200 x 4000
Day's Range1.7200 - 1.8300
52 Week Range1.6700 - 17.6500
Volume5,353,759
Avg. Volume5,234,404
Market Cap356.543M
Beta (5Y Monthly)4.58
PE Ratio (TTM)N/A
EPS (TTM)-0.2530
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.60
  • GlobeNewswire

    Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 40,092 shares of common stock to five

  • GlobeNewswire

    Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

    Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized as COVAXIN™ MALVERN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the publication “A comprehensive review of BBV

  • GlobeNewswire

    Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

    MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, PhD, will be among the featured speakers at the 3rd Annual Gene Therapy for Ophthalmic Disorders conference, which is being held Sept. 13-16 in Danvers, Massachusetts. Details regarding Dr. Upad

Advertisement
Advertisement